- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
[VIRTUAL] COVID-19 INFECTION IN HEMODIALYSIS POPULATION (Mini-Orals Hall) - Mar 19, 2021 - Abstract #ERAEDTA2021ERA_EDTA_659;
This study highlights the increased susceptibility of HD population to COVID-19 infection, which is associated with high rate of mortality, although lower than mortality rates reported in Europe and the united states. 5,6
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Effectiveness of lopinavir/ritonavir on covid-19 related pneumonia in a child with Covid-19 associated Kawasaki disease. (Pubmed Central) - Mar 19, 2021
The large outbreak of coronavirus disease 2019 (COVID-19) is spreading all over the world rapidly. There have recently been publications in the literature regarding the relationship between COVID 19 and Kawasaki disease but there is no sufficient knowledge about treatment and follow-up.Here, a pediatric case with Kawasaki disease associated with 2019-nCoV infection and successful treatment of covid-19 related pneumonia with lopinavir/ritonavir is reported.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Journal: Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019. (Pubmed Central) - Mar 19, 2021
In the YDJDG group, the mean duration of fever and pulmonary exudative lesions was significantly shorter than that observed in the lopinavir-ritonavir group (p = 0.0180 and p = 0.0028, respectively). YDJDG reveals the potential to hasten the recovery period in COVID-19 patients with mild/moderate disease type or CD4 < 660 cells/µL by shortening the mean duration of fever and pulmonary exudative lesions.
- |||||||||| sirolimus / Generic mfg.
Preclinical, Journal: Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro. (Pubmed Central) - Mar 18, 2021
Similarly, among the three drugs with an anti-HCoV-229E activity, namely lopinavir/ritonavir, chloroquine and resveratrol, only the latter showed a reduction of the viral titer on SARS-CoV-2 with reduced cytotoxicity. This opens the door to further evaluation to fight Covid-19.
- |||||||||| lopinavir/ritonavir / Generic mfg.
[VIRTUAL] PRETERM BIRTH, BREASTFEEDING, ANTENATAL ARV REGIMEN, AND 24-MONTH HIV-FREE SURVIVAL () - Mar 18, 2021 - Abstract #CROI2021CROI_797;
In PROMISE, PT birth <37 weeks was significantly associated with lower 24 month HIV-free survival, while BF was associated with increased HIV-free survival. Finding Interventions to decrease risk of PT birth for HIV+ mothers and prevent related infant deaths remain a high priority.
- |||||||||| hydroxychloroquine / Generic mfg., enoxaparin sodium / Generic mfg.
Clinical, Journal: Clinical and Therapeutic Approach to Hospitalized COVID-19 Patients: A Pediatric Cohort in Portugal. (Pubmed Central) - Mar 16, 2021
A significant proportion of our population presented severe and critical disease, was hospitalized and received treatment according to the most recent data, although most patients had mild disease. COVID-19 treatment in children is a clinical challenge and clinical trials are urgently needed.
- |||||||||| hydroxychloroquine / Generic mfg.
[VIRTUAL] ORAL BACTERIOTHERAPY IN THE MANAGEMENTE OF FATIGUE IN COVID-19 PATIENTS (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_3275;
Obtained results strongly evidenced that oral bacteriotherapy could represent a promising therapeutic strategy in reducing fatigue and preventing CFS development above all in fragile subjects. Furthermore, our findings contribute to stress the importance of the modulation of gut microbiota in influencing the outcome of Covid-19 patients.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
[VIRTUAL] ORAL BACTERIOTHERAPY IN PATIENTS WITH COVID-19: A RETROSPECTIVE COHORT STUDY (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_3272;
By multivariate analysis, the age >65 years, PCR >41.8 mg/L, Platelets <150.000 mmc, and CV events were associated with increased mortality risk. Overall results evidenced that oral bacteriotherapy with SLAB51 was an independent variable associated with a reduced risk for death.
- |||||||||| Review, Journal: Review of investigational drugs for coronavirus disease 2019. (Pubmed Central) - Mar 11, 2021
Despite multitude of treatment options available, treatment of choice is still not well established. Moreover, optimum supportive care and monitoring of seriously ill patients is the need of the hour.
- |||||||||| hydroxychloroquine / Generic mfg., piperacillin sodium/tazobactam sodium / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Sudden neck swelling with rash as late manifestation of COVID-19: a case report. (Pubmed Central) - Mar 10, 2021
Moreover, optimum supportive care and monitoring of seriously ill patients is the need of the hour. Sudden neck swelling with rash may be a coincidental presentation, but, in the pandemic context, it is most likely a direct or indirect complication of COVID-19.
- |||||||||| Arbidol (umifenovir) / Pharmstandard, rSIFN-co / Sichuan Huiyang Life Sci
Clinical, Journal: Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. (Pubmed Central) - Mar 9, 2021
rSIFN-co therapy alone or combined with other antiviral therapy is worth to be further studied.Key messagesThere are few effective therapies for coronavirus disease 2019 (COVID-19) upon the outbreak of the pandemic. Interferon alphas, by inducing both innate and adaptive immune responses, have shown clinical efficacy in treating severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus.In this multicenter, head-to-head, randomized, clinical trial which included 94 participants with moderate-to-severe COVID-19, the rSIFN-co plus antiviral agents (lopinavir-ritonavir or umifenovir) was associated with a shorter time of clinical improvement than interferon-alpha plus antiviral agents.
- |||||||||| ritonavir / Generic mfg.
Clinical, Journal: Comparison of clinically approved molecules on SARS-CoV-2 drug target proteins: a molecular docking study. (Pubmed Central) - Mar 9, 2021
Remdesivir, a nucleic acid derivative, strongly bound to the active site of this protease, suggesting that this molecule can be used as a template for designing novel furin protease inhibitors to fight against the disease. Protein-drug interactions revealed in this study at the molecular level, can pave the way for better drug design for each specific target.
- |||||||||| Aerodone (aerosol pirfenidone) / McMaster University, Avalyn Pharma, Esbriet (pirfenidone) / Shionogi, Roche
Clinical, Review, Journal: Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. (Pubmed Central) - Mar 7, 2021
Furthermore, novel pharmaceutical formulations of older agents (e.g., aerosolized administration of chloroquine/hydroxychloroquine, remdesivir, heparin, pirfenidone) have been tested in order to increase pulmonary delivery and/or antiviral effects of potentially active drugs, thus overcoming pharmacokinetic issues. In our review, we will highlight the importance of the drug repurposing strategy in the context of COVID-19, including regulatory and ethical aspects, with a specific focus on novel pharmaceutical formulations and routes of administration.
- |||||||||| chloroquine phosphate / Generic mfg., hydroxychloroquine / Generic mfg.
Review, Journal: Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. (Pubmed Central) - Mar 5, 2021
These results make it less likely that the drug is effective in protecting people from infection, although this is not excluded entirely. It is probably sensible to complete trials examining prevention of infection, and ensure these are carried out to a high standard to provide unambiguous results.
- |||||||||| remdesivir / Generic mfg., chloroquine phosphate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Review, Journal: THE PECULIARITY OF COVID- 19 GENOME AND THE CORONAVIRUS RNA TRANSLATION PROCESS AS APOTENTIAL TARGET FOR ETIOTROPIC MEDICATIONSWITH ADENINE AND OTHER NUCLEOTIDE ANALOGUES (REVIEW). (Pubmed Central) - Mar 5, 2021
Among the drugs listed above, lopinavir acts through this mechanism but is characterized by severe side effects.It is emphasized that remdesivir as adenosine analog provides inhibitory action on RNA dependent RNA-Polymerase,but there are controversial views about reduction in mortality during using of this drug against COVID-19. The present paper discusses the mechanism of action of a potential etiotropic drug against coronavirus, which implies the replacement of the nucleotides involved in the process of translation of the virus with their analogs with the aim to "inhibit" the ribosome and block the production of viral proteins.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: Gut, metabolism and nutritional Support for COVID-19: Experiences from China. (Pubmed Central) - Mar 4, 2021
Secondly, for patients receiving the antiviral agents lopinavir/ritonavir, gastrointestinal side effects should be monitored for and timely intervention provided...Fifthly, supplemental parenteral nutrition should be used with caution. Lastly, omega-3 fatty acids may be used as immunoregulators, intravenous administration of omega-3 fatty emulsion (10 g/day) at an early stage may help to reduce the inflammatory reaction.
- |||||||||| Enrollment closed, Trial completion date, Trial primary completion date: Antiretroviral Regime for Viral Eradication in Newborns (clinicaltrials.gov) - Mar 3, 2021
P4, N=600, Active, not recruiting,
Lastly, omega-3 fatty acids may be used as immunoregulators, intravenous administration of omega-3 fatty emulsion (10 g/day) at an early stage may help to reduce the inflammatory reaction. Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Retrospective data, Journal: Clinical presentation, case management and outcomes for the first 32 COVID-19 patients in Nigeria. (Pubmed Central) - Mar 3, 2021
Almost all (97%) the patients were treated with lopinavir-ritonavir with no recorded death...In this preliminary analysis of the first COVID-19 cases in Nigeria, clinical presentation was mild to moderate with no mortality. Processes to improve promptness of admission and reduce hospital stay are required to enhance the response to COVID-19 in Nigeria.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, Journal: Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. (Pubmed Central) - Mar 2, 2021
This post-marketing study in a real-world setting suggests that the use of remdesivir is significantly associated with an increased risk of reporting bradycardia and serious bradycardia when compared with the use of with hydroxychloroquine, lopinavir/ritonavir, tocilizumab or glucocorticoids. This result is in line with pharmacodynamic properties of the remdesivir.
- |||||||||| chloroquine phosphate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Review, Journal: COVID-19 and the burning issue of drug interaction: never forget the ECG. (Pubmed Central) - Feb 27, 2021
This brief review focuses the attention on the most relevant drug interactions involving the currently used COVID-19 medications and their possible association with cardiac rhythm disorders, taking into account also pre-existing condition and precipitating factors that might additionally increase this risk. Furthermore, based on the available evidence and based on the knowledge of drug interaction, we propose a quick and simple algorithm that might help both cardiologists and non-cardiologists in the management of the arrhythmic risk before and during the treatment with the specific drugs used against SARS-CoV2.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, Review, Journal: A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients. (Pubmed Central) - Feb 27, 2021
The treatments have been used before side effects occur, included: antimalarial, anti-viral, antibiotics, tocilizumab, enoxaparin and and so on...Antivirals, antimalarials, azithromycin, and tocilizumab are most responsive drugs for adverse drug reactions, but antivirals especially in combination with antimalarial drugs are in the first step...Lopinavir/ritonavir is the most prevalent used drug among antivirals with the highest skin adverse reaction; ribarivin and remdisivir also could induce cutaneous drug reactions but favipiravir has no or less adverse effects...Rarely, potentially life-threatening reactions may occur. Better management strategies could achieve by knowing more about drug-induced mucocutaneous presentations of COVID-19.
- |||||||||| Journal: Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum. (Pubmed Central) - Feb 27, 2021
The presented method is suitable for accurate and simultaneous quantification of remdesivir, its metabolite GS-441525, chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin in human serum. The quantitative assay may be an efficient tool for the therapeutic drug monitoring of these potential drug candidates in COVID-19 patients in order to increase treatment efficacy and safety.
- |||||||||| dexamethasone / Generic mfg.
Clinical, Retrospective data, Review, Journal: An updated systematic review and network meta-analysis of 25 randomized trials assessing the efficacy and safety of treatments in COVID-19 disease. (Pubmed Central) - Feb 27, 2021
Compared to standard care, remdesivir for both 5 and 10 days, lopinavir/ritonavir, and dexamethasone reduced the risk of any severe AEs by 52% (0.48, 0.34-0.67), 24% (0.77, 0.63-0.92), 40% (0.60, 0.37-0.98), and 50% (0.50, 0.25-0.98) respectively. In this study of hospitalized patients with COVID-19, administration of remdesivir for 10-day compared to standard care was associated with lower 28-day all-cause mortality and serious AEs, and higher clinical improvement rate.
- |||||||||| remdesivir / Generic mfg., hydroxychloroquine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2. (Pubmed Central) - Feb 26, 2021
Antiviral therapy for COVID-19 is not necessary for the great majority of pediatric patients. For children with severe or critical disease, this guidance offers an approach for decision-making regarding use of remdesivir.
|
